Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

BACKGROUND: Dotinurad is a novel selective urate reabsorption inhibitor that reduces serum urate levels in hyperuricemic patients with or without gout by selectively inhibiting urate transporter 1. This study was conducted to compare the efficacy and safety of dotinurad with those of benzbromarone....

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Sano, Takafumi, Sasaki, Tomomitsu, Fushimi, Masahiko, Ohashi, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066104/
https://www.ncbi.nlm.nih.gov/pubmed/31980978
http://dx.doi.org/10.1007/s10157-020-01849-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066104/
https://www.ncbi.nlm.nih.gov/pubmed/31980978
http://dx.doi.org/10.1007/s10157-020-01849-0

Ejemplares similares